| Browse All

Tango Therapeutics, Inc. (TNGX)

Healthcare | Biotechnology | Boston, United States | NasdaqGM
26.64 USD +1.60 (6.390%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 27.18 +0.54 (2.027%) ⇧ (April 17, 2026, 7:05 p.m. EDT)

Short-term: ★★★★☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 18, 2026, 10:42 p.m. EDT

TNGX presents a dangerous asymmetry suitable only for aggressive momentum traders. While fundamental metrics (negative EPS, massive cash burn, deteriorating revenue) clearly rate it a 0 for a long-term buy, the technical setup and sparse puts signaling extremely low downside risk in the immediate term. However, the 0.32% short ratio combined with management selling and a negative revenue growth rate suggests this rally is likely based on hype rather than sustainable business value accumulation.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.213372
AutoARIMA0.306091
AutoETS0.306092
MSTL0.318239

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 40%
H-stat 204.28
Ljung-Box p 0.000
Jarque-Bera p 0.155
Excess Kurtosis -1.41
Attribute Value
Sector Healthcare
Debt to Equity Ratio 9.697
Revenue per Share 0.537
Market Cap 3,801,230,848
Forward P/E -16.65
Beta 1.32
Profit Margins -162.85%
Website https://www.tangotx.com

As of April 18, 2026, 10:42 p.m. EDT: Options flow shows a distinct bullish skew for the near term. At the May 15 expiration, there is significant volume at the 22.0 strike (110 contracts vs low Open Interest), indicating strong speculation of a move above current prices ($26.64), while ATM calls see high volume at 27.0. Conversely, put activity is sparse and concentrated deep out-of-the-money, with negligible expiration before 2026-11-20. The 2027-01-15 strikes show heavy OTM put positioning (240+ contracts at 17.0 strike on the open interest side), suggesting long-term downside insurance rather than immediate selling pressure, while no OTM calls exist on that front.


Info Dump

Attribute Value
52 Week Change 18.304348
Address1 201 Brookline Avenue
Address2 Suite 901
All Time High 26.81
All Time Low 1.03
Ask 26.84
Ask Size 27
Audit Risk 8
Average Analyst Rating 1.3 - Strong Buy
Average Daily Volume10 Day 2,832,840
Average Daily Volume3 Month 3,239,264
Average Volume 3,239,264
Average Volume10Days 2,832,840
Beta 1.315
Bid 26.38
Bid Size 27
Board Risk 3
Book Value 2.547
City Boston
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 8
Country United States
Crypto Tradeable 0
Currency USD
Current Price 26.64
Current Ratio 16.318
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 26.81
Day Low 24.92
Debt To Equity 9.697
Display Name Tango Therapeutics
Earnings Timestamp 1,772,717,400
Earnings Timestamp End 1,778,502,600
Earnings Timestamp Start 1,778,502,600
Ebitda -109,008,000
Ebitda Margins -1.74737
Enterprise To Ebitda -32.031
Enterprise To Revenue 55.97
Enterprise Value 3,491,663,104
Eps Current Year -1.33818
Eps Forward -1.6
Eps Trailing Twelve Months -0.87
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 17.0228
Fifty Day Average Change 9.617199
Fifty Day Average Change Percent 0.5649599
Fifty Two Week Change Percent 1,830.4348
Fifty Two Week High 26.81
Fifty Two Week High Change -0.17000008
Fifty Two Week High Change Percent -0.0063409205
Fifty Two Week Low 1.03
Fifty Two Week Low Change 25.609999
Fifty Two Week Low Change Percent 24.864077
Fifty Two Week Range 1.03 - 26.81
Financial Currency USD
First Trade Date Milliseconds 1,599,139,800,000
Float Shares 67,744,386
Forward Eps -1.6
Forward P E -16.65
Free Cashflow -60,859,624
Full Exchange Name NasdaqGM
Full Time Employees 137
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,775,001,600
Gross Margins -1.11857
Gross Profits -69,781,000
Has Pre Post Market Data 1
Held Percent Insiders 0.0126600005
Held Percent Institutions 1.21253
Implied Shares Outstanding 142,688,851
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Long Name Tango Therapeutics, Inc.
Market us_market
Market Cap 3,801,230,848
Market State CLOSED
Max Age 86,400
Message Board Id finmb_424111353
Most Recent Quarter 1,767,139,200
Net Income To Common -101,594,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 3,801,230,990
Number Of Analyst Opinions 10
Open 25.31
Operating Cashflow -138,886,000
Operating Margins -1.7839301
Overall Risk 7
Payout Ratio 0.0
Phone 857 320 4900
Post Market Change 0.5400009
Post Market Change Percent 2.0270305
Post Market Price 27.18
Post Market Time 1,776,467,116
Previous Close 25.04
Price Eps Current Year -19.907637
Price Hint 2
Price To Book 10.459364
Price To Sales Trailing12 Months 60.932785
Profit Margins -1.62853
Quick Ratio 15.828
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.25
Region US
Regular Market Change 1.6
Regular Market Change Percent 6.38977
Regular Market Day High 26.81
Regular Market Day Low 24.92
Regular Market Day Range 24.92 - 26.81
Regular Market Open 25.31
Regular Market Previous Close 25.04
Regular Market Price 26.64
Regular Market Time 1,776,456,000
Regular Market Volume 2,781,109
Return On Assets -0.19451
Return On Equity -0.37235
Revenue Growth -1.0
Revenue Per Share 0.537
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 8
Shares Outstanding 142,688,851
Shares Percent Shares Out 0.2829
Shares Short 40,370,279
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 48,739,116
Short Name Tango Therapeutics, Inc.
Short Percent Of Float 0.32509997
Short Ratio 9.95
Source Interval 15
State MA
Symbol TNGX
Target High Price 30.0
Target Low Price 16.0
Target Mean Price 22.3
Target Median Price 20.5
Total Cash 343,137,984
Total Cash Per Share 2.405
Total Debt 33,570,000
Total Revenue 62,384,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.87
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 10.472175
Two Hundred Day Average Change 16.167824
Two Hundred Day Average Change Percent 1.543884
Type Disp Equity
Volume 2,781,109
Website https://www.tangotx.com
Zip 2,215